Ultrasound-Guided Continuous Thoracic Paravertebral Infusion of Methylene Blue in the Treatment of Postherpetic Neuralgia: A Prospective, Randomized, Controlled Study

Mingxia Wang,Jinyuan Zhang,Li Zheng,Hongwei Fang,Yiguo Zhang,Huimin Deng,Mansi Wang,Xiuqin Yu,Qingxiang Meng,Yuanli Chen,Lijun Liao,Xin Lv,Hao Yang,Xiangrui Wang

DOI: https://doi.org/10.1007/s40122-021-00265-w

IF: 3.96

2021-04-11

Pain and Therapy

Abstract:IntroductionPostherpetic neuralgia (PHN) is the most common complication of herpes zoster. Methylene blue (MB) is an inhibitor of nitric oxide synthesis with potentially analgesic and anti-inflammatory properties. Studies have demonstrated that thoracic paravertebral single MB injection is effective in treating chronic pain. However, there are rare reports of the efficacy of continuous thoracic paravertebral infusion of MB for pain management in PHN patients. The purpose of this study was to evaluate the therapeutic effects of continuous thoracic paravertebral infusion of MB on PHN.MethodsA total of 104 PHN patients were randomly divided into two groups: the control group (continuous thoracic paravertebral infusion of 5% lidocaine in a total volume of 300 ml) and the MB group (continuous thoracic paravertebral infusion of 5% lidocaine plus 0.2% MB in a total volume of 300 ml). All patients were evaluated using the Numerical Rating Scale (NRS), Insomnia Severity Index (ISI), Patient Health Questionnaire-9 (PHQ-9), 36-Item Short-Form Health Survey (SF-36), and medication doses before and after the procedure. The effective treatment rate and adverse complications were recorded 6 months after the procedure.ResultsIn both groups, the NRS scores, ISI scores, PHQ-9 scores, and rescue medication dosages were significantly decreased at different time points after treatment compared to baseline, while the SF-36 scores were evidently improved at different time points after treatment compared to baseline. Compared with the control group, the MB group had significantly reduced NRS scores, ISI scores, PHQ-9 scores, and rescue medication dosages at each observation time point. Furthermore, the SF-36 scores in the MB group were significantly higher than those in the control group at each observation time point. The total effective treatment rate of the MB group was higher than that of the control group 6 months after the procedure. No severe adverse complications were observed in either group.ConclusionsUltrasound-guided continuous thoracic paravertebral infusion with MB is a safe and effective therapy for PHN. Continuous infusion with MB can significantly reduce pain intensity, improve pain-related depression, increase quality of life, and decrease the amount of rescue medicine with no serious adverse complications.

clinical neurology

What problem does this paper attempt to address?

The paper aims to study the efficacy and safety of Methylene Blue (MB) in the treatment of Postherpetic Neuralgia (PHN). Specifically, the study evaluates the therapeutic effects of continuous thoracic paravertebral space infusion of Methylene Blue under ultrasound guidance in PHN patients through a prospective, randomized, controlled trial. The main focus includes the reduction of pain intensity, improvement of related depressive symptoms, enhancement of quality of life, and reduction of the required rescue medication dosage. Additionally, it explores whether this method can provide safe and effective long-term analgesic effects. The study results show that, compared to the control group, the MB group had significantly lower pain scores, insomnia scores, depression scores, and rescue medication dosages at various observation time points, while the quality of life was significantly improved, and no serious adverse reactions occurred. Therefore, the study concludes that continuous thoracic paravertebral space infusion of Methylene Blue under ultrasound guidance is a safe and effective treatment method for PHN.